Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report sent to investors on Sunday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

NASDAQ:EGRX opened at $5.50 on Friday. The stock’s fifty day moving average is $4.25 and its 200 day moving average is $4.93. Eagle Pharmaceuticals has a fifty-two week low of $3.21 and a fifty-two week high of $23.52. The firm has a market capitalization of $71.45 million, a PE ratio of 4.66 and a beta of 0.50.

Institutional Trading of Eagle Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD purchased a new stake in Eagle Pharmaceuticals during the 1st quarter valued at $83,000. Vanguard Group Inc. increased its stake in Eagle Pharmaceuticals by 0.4% in the first quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock worth $3,358,000 after purchasing an additional 2,630 shares during the period. Headlands Technologies LLC increased its stake in Eagle Pharmaceuticals by 75.7% in the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock worth $35,000 after purchasing an additional 2,861 shares during the period. DGS Capital Management LLC increased its stake in Eagle Pharmaceuticals by 442.5% in the first quarter. DGS Capital Management LLC now owns 61,944 shares of the specialty pharmaceutical company’s stock worth $325,000 after purchasing an additional 50,525 shares during the period. Finally, Los Angeles Capital Management LLC increased its stake in Eagle Pharmaceuticals by 110.1% in the first quarter. Los Angeles Capital Management LLC now owns 191,732 shares of the specialty pharmaceutical company’s stock worth $1,005,000 after purchasing an additional 100,470 shares during the period. Hedge funds and other institutional investors own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.